Publications by authors named "B M Gershman"
Although clinical trials should be accessible to all patients, persistent racial and ethnic disparities in clinical trial enrollment exist. Herein, we examine racial disparities in clinical trial enrollment among prostate cancer patients from a large population-based cohort of oncology practices in the United States. Using CancerLinQ Discovery, we identified men with regional (N1+) and/or metastatic (M1) prostate cancer diagnosed from 2011 to 2023.
View Article and Find Full Text PDFArticle Synopsis
- Small cell prostate cancer (SCPC) is a rare, aggressive cancer with limited treatment guidelines, prompting this study to assess patient data and outcomes.
- The study analyzed 74 patients treated between 2010-2023, finding that most had metastatic disease and the primary treatment was platinum chemotherapy plus etoposide, with a median overall survival of 8.3 months for those with metastatic SCPC.
- Results showed that cisplatin plus etoposide improved survival over carboplatin plus etoposide, but there is no clear consensus on the best treatment, highlighting the need for further research in real-world clinical practices.
Introduction: Although the Prostate Imaging-Reporting and Data System (PI RADS) categorization represents the standard method for assessing the risk of prostate cancer using prostate magnetic resonance imaging (MRI), there exists wide variation in cancer detection rates (CDRs) in real-world practice. We therefore evaluated the association of clinical and radiographic features with CDRs and developed a predictive model to improve clinical management.
Methods: We identified men aged 18-89 years with elevated prostate-specfic antigen (PSA) or on active surveillance for prostate cancer who underwent MRI-ultrasound (US) fusion biopsy or in-bore MRI-targeted biopsy.
Background: Inflammation has been linked to the development of benign prostatic hyperplasia (BPH). SRD5A2 is a pivotal enzyme in the development and growth of the prostate gland and a critical target for BPH therapy. TNF-α regulates epigenetic changes in SRD5A2, leading to suppression of SRD5A2 gene and protein expression.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to enhance understanding of upper tract imaging in patients assessed for hematuria, evaluating imaging rates and effectiveness using a national cohort of insured individuals.
- A total of 466,710 patients were analyzed between 2010 and 2015, with various imaging modalities revealing low detection rates: ultrasound (1%), CT (1.7%), and other methods (2.7%).
- The results suggest that while the diagnostic yield of imaging is higher than expected, overall detection remains low, indicating a potential preference for using ultrasound in initial evaluations based on updated guidelines.